Company news
Dimerix Limited (ASX:DXB) news
Dimerix Limited news releases on 6ix. Latest, Oct 15, 2021: Phase 3 DMX-200 COVID-19 Study Expands into Australia
Press releases — page 3
Phase 3 DMX-200 COVID-19 Study Expands into Australia
October 14, 2021
Dimerix Closes SPP Oversubscribed
September 30, 2021
DMX-200 CLARITY COVID-19 Study Approval in India
September 24, 2021
Phase 3 Study in FSGS Kidney Patients Commences
August 24, 2021
SPP and Options Prospectus
August 23, 2021
Response to ASX Query
August 19, 2021
Successful $20m Placement to Fund Phase 3 Trials
August 15, 2021
DMX-200 COVID-19 Study Opens More Sites in Europe and UK
August 1, 2021
FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
July 18, 2021
Dimerix Receives Innovation Passport and ILAP Designation
June 6, 2021
Dimerix Confirms Phase 3 FSGS Study Design With EMA
June 3, 2021
DMX-200 Remains Eligible for Accelerated Approval
May 27, 2021
COVID-19 Study Recruits Multiple Patients in Europe
April 22, 2021
Major Shareholder Loan for $5 Million
March 29, 2021
Clinical Study in Patients with COVID-19 Progresses
March 24, 2021
DMX-200 Competitive Position Further Enhanced
March 23, 2021
CLARITY 2.0 Study Progresses In Patients With COVID-19
March 9, 2021
Appendix 4D and Interim Financial Report
February 21, 2021
Dimerix Plans for Next Study in Diabetic Kidney Disease
January 27, 2021
Second Study to Include DMX-200 in COVID-19 Patients
November 29, 2020
ARDS in COVID-19 Patients Protocol Published
November 8, 2020
Positive Additional Data to Support DMX-200 Development
October 26, 2020
Receipt of R&D Tax Incentive
October 20, 2020
DMX-700 Data Demonstrates Effect on Key COPD Receptors
October 6, 2020
Positive Top-Line Results in DKD Phase 2 Clinical Study
September 13, 2020
Dimerix Awarded $1 Million MRFF Funding
September 2, 2020
Positive Top-Line Results in FSGS Phase 2a Clinical Study
July 28, 2020
Last Patient Completes Dosing in DKD Phase 2 Clinical Study
July 23, 2020
Dimerix Completes $5.8m Placement
June 22, 2020
Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
June 16, 2020
Global REMAP-CAP Platform Trial Protocol To Include DMX-200
June 3, 2020
R&D Tax Incentive Facility
April 2, 2020
DMX-200 Treatment Continued Under TGA Special Access Scheme
March 2, 2020
Half Yearly Report and Accounts
February 18, 2020
Quarterly Commentary & Appendix 4C
January 20, 2020
DMX-200 Clinical Trial Update
January 6, 2020
Dimerix Completes $2.5m Placement
December 2, 2019
Dimerix Holds Pre-IND Meeting on DMX-200 With FDA
November 24, 2019
New Drug Pipeline Candidate DMX-700 & Company Update
October 9, 2019
DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment
September 25, 2019
DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited
July 9, 2019
DMX-200 Clinical Update
June 25, 2019
Dimerix Signs Licence Agreement for Receptor-HIT Technology
June 23, 2019
DMX-200 Manufacturing Update
May 26, 2019
Appendix 4C - quarterly
April 26, 2019
Appendix 4C and Quarterly Highlights
January 30, 2019
Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
December 19, 2018
1st Patient Dosed in DMX-200 Clinical Trial for FSGS
November 21, 2018
DXB Receives Orphan Drug Designation in EU
November 20, 2018
FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIAL
November 19, 2018